314 related articles for article (PubMed ID: 34878825)
1. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Katsarou A; Sjöstrand M; Naik J; Mansilla-Soto J; Kefala D; Kladis G; Nianias A; Ruiter R; Poels R; Sarkar I; Patankar YR; Merino E; Reijmers RM; Frerichs KA; Yuan H; de Bruijn J; Stroopinsky D; Avigan D; van de Donk NWCJ; Zweegman S; Mutis T; Sadelain M; Groen RWJ; Themeli M
Sci Transl Med; 2021 Dec; 13(623):eabh1962. PubMed ID: 34878825
[TBL] [Abstract][Full Text] [Related]
2. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
[TBL] [Abstract][Full Text] [Related]
6. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
[No Abstract] [Full Text] [Related]
8. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
Front Immunol; 2022; 13():836549. PubMed ID: 35222427
[TBL] [Abstract][Full Text] [Related]
9. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
10. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
11. CAR T-cell therapy for multiple myeloma: state of the art and prospects.
van de Donk NWCJ; Usmani SZ; Yong K
Lancet Haematol; 2021 Jun; 8(6):e446-e461. PubMed ID: 34048683
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy: is it prime time in myeloma?
Sidana S; Shah N
Blood Adv; 2019 Nov; 3(21):3473-3480. PubMed ID: 31714964
[TBL] [Abstract][Full Text] [Related]
13. Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells.
Wang Y; Zhong K; Ke J; Chen X; Chen Y; Shu W; Chen C; Hu S; Sun X; Huang H; Luo C; Liu L; Yang J; Zhang Y; Zhi H
Cytotherapy; 2021 Aug; 23(8):715-723. PubMed ID: 33863641
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
15. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
16. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Ghorashian S; Kramer AM; Onuoha S; Wright G; Bartram J; Richardson R; Albon SJ; Casanovas-Company J; Castro F; Popova B; Villanueva K; Yeung J; Vetharoy W; Guvenel A; Wawrzyniecka PA; Mekkaoui L; Cheung GW; Pinner D; Chu J; Lucchini G; Silva J; Ciocarlie O; Lazareva A; Inglott S; Gilmour KC; Ahsan G; Ferrari M; Manzoor S; Champion K; Brooks T; Lopes A; Hackshaw A; Farzaneh F; Chiesa R; Rao K; Bonney D; Samarasinghe S; Goulden N; Vora A; Veys P; Hough R; Wynn R; Pule MA; Amrolia PJ
Nat Med; 2019 Sep; 25(9):1408-1414. PubMed ID: 31477906
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells.
Tan J; Jia Y; Zhou M; Fu C; Tuhin IJ; Ye J; Monty MA; Xu N; Kang L; Li M; Shao J; Fang X; Zhu H; Yan L; Qu C; Xue S; Jin Z; Chen S; Huang H; Xu Y; Chen J; Miao M; Tang X; Li C; Yan Z; Wu D; Yu L
J Hematol Oncol; 2022 Apr; 15(1):39. PubMed ID: 35365211
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial CAR design improves target restriction.
Köksal H; Dillard P; Juzeniene A; Kvalheim G; Smeland EB; Myklebust JH; Inderberg EM; Wälchli S
J Biol Chem; 2021; 296():100116. PubMed ID: 33234592
[TBL] [Abstract][Full Text] [Related]
19. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma.
Feng Y; Liu X; Li X; Zhou Y; Song Z; Zhang J; Shi B; Wang J
Oncoimmunology; 2021; 10(1):1959102. PubMed ID: 34434610
[TBL] [Abstract][Full Text] [Related]
20. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].
Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477
[No Abstract] [Full Text] [Related]
[Next] [New Search]